Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd ADR (NY: CANF )

2.430 -0.030 (-1.22%)
Streaming Delayed Price Updated: 2:56 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Can-Fite Biopharma Ltd ADR

< Previous 1 2 3 4 Next >
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Announces $10.0 Million Registered Direct Offering
From Can-Fite BioPharma Ltd.
Via Business Wire
Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Expands its Phase II COVID-19 Study to Europe
From Can-Fite BioPharma Ltd
Via Business Wire
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.